Conjugates and preparation and use thereof

1. A compound having a structure represented by Formula (321):

wherein,

n1 is an integer of 1-2, n3 is an integer of 0-1, and n1+n3=2-3;

each of m1, m2, and m3 is independently an integer of 2-10;

each of R 10 , R 11 , R 12 , R 13 , R 14 and R 15 is independently selected from H, C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, and C 1 -C 10 alkoxy;

R 4 is a moiety capable of binding to an active drug or active agentvia a covalent bond;

each L 1 is a linear alkylene of 1 to 70 carbon atoms in length, wherein one or more carbon atoms are optionally replaced with any one or more of the group consisting of: C(O), NH, O, S, CH═N, S(O) 2 , C 2 -C 10 alkenylene, C 2 -C 10 alkynylene, C 6 -C 10 arylene, C 3 -C 18 heterocyclylene, and C 5 -C 10 heteroarylene, and wherein L 1 is optionally substituted by any one or more of the group consisting of: C 1 -C 10 alkyl, C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 1 -C 10 haloalkyl, —OC 1 -C 10 alkyl, —OC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-OH, —OC 1 -C 10 haloalkyl, —SC 1 -C 10 alkyl, —SC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-SH, —SC 1 -C 10 haloalkyl, halo, —OH, —SH, —NH 2 , —C 1 -C 10 alkyl-NH 2 , —N(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —NH(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl)(C 1 -C 10 alkylphenyl), —NH(C 1 -C 10 alkylphenyl), cyano, nitro, —CO 2 H, —C(O)OC 1 -C 10 alkyl, —CON(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —CONH(C 1 -C 10 alkyl), —CONH 2 , —NHC(O)(C 1 -C 10 alkyl), —NHC(O)(phenyl), —N(C 1 -C 10 alkyl)C(O)(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl)C(O)(phenyl), —C(O)C 1 -C 10 alkyl, —C(O)C 1 -C 10 alkylphenyl, —C(O)C 1 -C 10 haloalkyl, —OC(O)C 1 -C 10 alkyl, —SO 2 (C 1 -C 10 alkyl), —SO 2 (phenyl), —SO 2 (C 1 -C 10 haloalkyl), —SO 2 NH 2 , —SO 2 NH(C 1 -C 10 alkyl), —SO 2 NH(phenyl), —NHSO 2 (C 1 -C 10 alkyl), —NHSO 2 (phenyl), and —NHSO 2 (C 1 -C 10 haloalkyl);

each S 1 is independently an M 1 , wherein any active hydroxyl, if any, is protected with a hydroxyl protecting group;

each M 1 is independently selected from a ligand capable of binding to a cell surface receptor; and

wherein the receptor is an asialoglycoprotein receptor on human hepatocytes.

2. The compound according to claim 1 , wherein each L 1 is independently selected from the group consisting of groups A1-A26 and any combinations thereof:

wherein each j1 is independently an integer of 1-20;

each j2 is independently an integer of 1-20;

each R′ is independently a C 1 -C 10 alkyl;

each Ra is independently selected from the group consisting of A27-A45 and any combinations thereof:

each Rb is independently a C 1 -C 10 alkyl; and

represents a site where a group is attached to the rest of the molecule.

3. The compound according to claim 2 , wherein L 1 is selected from the group consisting of groups A1, A4, A5, A6, A8, A10, A11, A13, and connection combinations thereof.

4. The compound according to claim 1 , wherein the length of L 1 is 3 to 25 atoms, wherein the length of L 1 refers to the number of chain-forming atoms in L 1 within the longest atom chain formed from the atom linked to the N atom on the nitrogenous backbone to the atom linked to S 1 .

5. The compound according to claim 1 , wherein each of m1, m2 and m3 is independently an integer of 2-5, or m1=m2=m3.

6. The compound according to claim 1 , wherein each M 1 is independently selected from the group consisting of D-mannopyranose, L-mannopyranose, D-arabinose, D-xylofuranose, L-xylofuranose, D-glucose, L-glucose, D-galactose, L-galactose, α-D-mannofuranose, β-D-mannofuranose, α-D-mannopyranose, β-D-mannopyranose, α-D-glucopyranose, β-D-glucopyranose, α-D-glucofuranose, β-D-glucofuranose, α-D-fructofuranose, α-D-fructopyranose, α-D-galactopyranose, β-D-galactopyranose, α-D-galactofuranose, β-D-galactofuranose, glucosamine, sialic acid, galactosamine, N-acetylgalactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, N-isobutyrylgalactosamine, 2-amino-3-O—[(R)-1-carboxyethyl]-2-deoxy-β-D-glucopyranose, 2-deoxy-2-methylamino-L-glucopyranose, 4,6-dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose, 2-deoxy-2-sulfoamino-D-glucopyranose, N-glycolyl-α-neuraminic acid, 5-thio-β-D-glucopyranose, methyl 2,3,4-tris-O-acetyl-1-thio-6-O-trityl-α-D-glucopyranoside, 4-thio-β-D-galactopyranose, ethyl 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-α-D-glucoheptopyranoside, 2,5-anhydro-D-allononitrile, ribose, D-ribose, D-4-thioribose, L-ribose, and L-4-thioribose.

7. The compound according to claim 1 , wherein R 4 is a group capable of binding to an oligonucleotide via a phosphodiester bond.

8. The compound according to claim 1 , wherein R 4 comprises a first functional group that can react with a group on an oligonucleotide or a nucleotide to form a phosphate ester bond.

9. The compound according to claim 8 , wherein R 4 further comprises a second functional group which is capable of forming a covalent bond with a hydroxy group or an amino group, or is a solid phase support attached to the rest of the molecule via a covalent bond formed with a hydroxy group or an amino group.

10. The compound according to claim 8 , wherein the first functional group is a phosphoramidite, a hydroxy or a protected hydroxy.

11. The compound according to claim 9 , wherein the second functional group is a phosphoramidite group, a carboxyl or a carboxylate.

12. The compound according to claim 8 , wherein the compound has a structure represented by Formula (403)-(442):

wherein X is O or NH, M + is a cation, R k is a hydroxy protecting group, SPS represents a solid phase support.

13. The compound according to claim 12 , wherein M + is an alkali metal cation, an ammonium cation, a cation formed from a tertiary amine, or a quaternary ammonium cation, R k is trityl, 4-methoxytrityl, 4,4′-dimethoxytrityl, or 4,4′,4″-trimethoxytrityl, and SPS represents a resin.

14. A conjugate having a structure represented by Formula (1):

wherein,

n1 is an integer of 1-2, n3 is an integer of 0-1, and n1+n3=2-3;

each of m1, m2, and m3 is independently an integer of 2-10;

each of R10, R11, R12, R13, R14 and R15 is independently selected from H, C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, and C 1 -C 10 alkoxy;

R 3 is an active drug;

R 2 is a linear alkylene of 1 to 20 carbon atoms in length, wherein one or more carbon atoms are optionally replaced with any one or more of the group consisting of: C(O), NH, O, S, CH═N, S(O) 2 , C 2 -C 10 alkeylene, C 2 -C 10 alkynylene, C 6 -C 10 arylene, C 3 -C 18 heterocyclylene, and C 5 -C 10 heteroarylene, and wherein R 2 is optionally substituted by any one or more of the group consisting of: C 1 -C 10 alkyl, C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 1 -C 10 haloalkyl, —OC 1 -C 10 alkyl, —OC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-OH, —OC 1 -C 10 haloalkyl, —SC 1 -C 10 alkyl, —SC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-SH, haloalkyl, halo, —OH, —SH, —NH 2 , —C 1 -C 10 alkyl-NH 2 , —N(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —NH(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl)(C 1 -C 10 alkylphenyl), —NH(C 1 -C 10 alkylphenyl), cyano, nitro, —CO 2 H, —C(O)OC 1 -C 10 alkyl, —CON(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —CONH(C 1 -C 10 alkyl), —CONH 2 , —NHC(O)(C 1 -C 10 alkyl), —NHC(O)(phenyl), —N(C 1 -C 10 alkyl)C(O)(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl)C(O)(phenyl), —C(O)C 1 -C 10 alkyl, —C(O)C 1 -C 10 alkylphenyl, —C(O)C 1 -C 10 haloalkyl, —OC(O)C 1 -C 10 alkyl, —SO 2 (C 1 -C 10 alkyl), —SO 2 (phenyl), —SO 2 (C 1 -C 10 haloalkyl), —SO 2 NH 2 , —SO 2 NH(C 1 -C 10 alkyl), —SO 2 NH(phenyl), —NHSO 2 (C 1 -C 10 alkyl), —NHSO 2 (phenyl), and —NHSO 2 (C 1 -C 10 haloalkyl);

each L 1 is independently a linear alkylene of 1 to 70 carbon atoms in length, wherein one or more carbon atoms are optionally replaced with any one or more of the group consisting of: C(O), NH, O, S, CH═N, S(O) 2 , C 2 -C 10 alkeylene, C 2 -C 10 alkynylene, C 6 -C 10 arylene, C 3 -C 18 heterocyclylene, and C 5 -C 10 heteroarylene, and wherein L 1 is optionally substituted by any one or more of the group consisting of: C 1 -C 10 alkyl, C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 1 -C 10 haloalkyl, —OC 1 -C 10 alkyl, —OC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-OH, —OC 1 -C 10 haloalkyl, —SC 1 -C 10 alkyl, —SC 1 -C 10 alkylphenyl, —C 1 -C 10 alkyl-SH, —SC 1 -C 10 haloalkyl, halo, —OH, —SH, —NH 2 , —C 1 -C 10 alkyl-NH 2 , —N(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —NH(C 1 -C 10 alkyl), alkyl)(C 1 -C 10 alkylphenyl), —NH(C 1 -C 10 alkylphenyl), cyano, nitro, —CO 2 H, —C(O)OC 1 -C 10 alkyl, —CON(C 1 -C 10 alkyl)(C 1 -C 10 alkyl), —CONH(C 1 -C 10 alkyl), —CONH 2 , —NHC(O)(C 1 -C 10 alkyl), —NHC(O)(phenyl), —N(C 1 -C 10 alkyl)C(O)(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl)C(O)(phenyl), —C(O)C 1 -C 10 alkyl, —C(O)C 1 -C 10 alkylphenyl, —C(O)C 1 -C 10 haloalkyl, —OC(O)C 1 -C 10 alkyl, —SO 2 (C 1 -C 10 alkyl), —SO 2 (phenyl), —SO 2 (C 1 -C 10 haloalkyl), —SO 2 NH 2 , —SO 2 NH(C 1 -C 10 alkyl), —SO 2 NH(phenyl), —NHSO 2 (C 1 -C 10 alkyl), —NHSO 2 (phenyl), and —NHSO 2 (C 1 -C 10 haloalkyl);

each M 1 is selected from one of ligands capable of binding to a cell surface receptor; and

wherein the receptor is an asialoglycoprotein receptor on human hepatocytes.

15. The conjugate according to claim 14 , wherein each L 1 is independently selected from the group consisting of groups A1-A26 and any combinations thereof:

wherein each j1 is independently an integer of 1-20;

each j2 is independently an integer of 1-20;

each R′ is independently a C 1 -C 10 alkyl;

each Ra is independently selected from the group consisting of A27-A45 and any combinations thereof:

each Rb is independently a C 1 -C 10 alkyl; and

represents a site where a group is attached to the rest of the molecule.

16. The conjugate according to claim 15 , wherein L 1 is selected from the group consisting of groups A1, A4, A5, A6, A8, A10, A11, A13, and connection combinations thereof.

17. The conjugate according to claim 14 , wherein the length of L 1 is 3 to 25 atoms.

18. The conjugate according to claim 14 , wherein each of m1, m2 and m3 is independently an integer of 2-5; or m1=m2=m3.

19. The conjugate according to claim 14 , wherein each M 1 is independently a monosaccharide, disaccharide, trisaccharide, or polysaccharide.

20. The conjugate according to claim 14 , wherein each M 1 is independently selected from the group consisting of D-mannopyranose, L-mannopyranose, D-arabinose, D-xylofuranose, L-xylofuranose, D-glucose, L-glucose, D-galactose, L-galactose, α-D-mannofuranose, β-D-mannofuranose, α-D-mannopyranose, 3-D-mannopyranose, α-D-glucopyranose, β-D-glucopyranose, α-D-glucofuranose, β-D-glucofuranose, α-D-fructofuranose, α-D-fructopyranose, α-D-galactopyranose, β-D-galactopyranose, α-D-galactofuranose, β-D-galactofuranose, glucosamine, sialic acid, galactosamine, N-acetylgalactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, N-isobutyrylgalactosamine, 2-amino-3-O—[(R)-1-carboxyethyl]-2-deoxy-β-D-glucopyranose, 2-deoxy-2-methylamino-L-glucopyranose, 4,6-dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose, 2-deoxy-2-sulfoamino-D-glucopyranose, N-glycolyl-α-neuraminic acid, 5-thio-β-D-glucopyranose, methyl 2,3,4-tris-O-acetyl-1-thio-6-O-trityl-α-D-glucopyranoside, 4-thio-β-D-galactopyranose, ethyl 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-α-D-glucoheptopyranoside, 2,5-anhydro-D-allononitrile, ribose, D-ribose, D-4-thioribose, L-ribose, and L-4-thioribose.

21. The conjugate according to claim 14 , wherein R 3 is a group having a structure represented by Formula A59:

wherein E 1 is OH, SH or BH 2 , and Nu is a functional oligonucleotide.

22. The conjugate according to claim 21 , wherein R 2 forms a phosphoester bond with the P atom in R 3 .

23. The conjugate according to claim 14 , wherein the conjugate has a structure represented by Formula (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), or (22):

24. The conjugate according to claim 21 , wherein the functional oligonucleotide is selected from the group consisting of small interfering RNA, microRNA, anti-microRNA, microRNA antagonist, microRNA mimics, decoy oligonucleotide, immune stimulatory, G-quadruplex, splice altering, single strand RNA, antisense nucleic acid, nucleic acid aptamer, stem-loop RNA, mRNA fragments, activating RNA, or DNA.

25. The conjugate according to claim 24 , wherein

the functional oligonucleotide is a single strand oligonucleotide, and the P atom in formula A59 is linked to 3′ terminal of the single strand oligonucleotide; or

the functional oligonucleotide is a double stranded oligonucleotide comprising a sense strand and an antisense strand, and the P atom in formula A59 is linked to 3′ terminal region of the sense strand.

26. The conjugate according to claim 25 , wherein the double stranded oligonucleotide is an siRNA, and each nucleotide in the siRNA is independently a modified or unmodified nucleotide; the siRNA contains a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence 1, and the antisense strand comprises a nucleotide sequence 2, both of which have a length of 19 nucleotides and are at least partly reverse complementary to form a double-stranded complementary region; the nucleotide sequence 2 is at least partly complementary to a first nucleotide sequence segment which refers to a segment of nucleotide in a target mRNA; and the target mRNA refers to a mRNA of a gene that is aberrantly expressed in hepatocytes.

27. The conjugate according to claim 26 , wherein the target mRNA is the mRNA corresponding to ApoB, ApoC, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV or HCV.

28. The conjugate according to claim 26 , wherein the nucleotide sequence 1 has the same length with the first nucleotide sequence segment and no more than 3 nucleotides different from the first nucleotide sequence segment; the nucleotide sequence 2 has the same length with a nucleotide sequence B and no more than 3 nucleotides different from the nucleotide sequence B, which refers to a nucleotide sequence completely reverse complementary to the first nucleotide sequence segment.

29. The conjugate according to claim 28 , wherein the nucleotide differences between the nucleotide sequence 2 and the nucleotide sequence B includes the difference at the site of the first nucleotide Z′ on the nucleotide sequence 2 from 5′ end to 3′ end.

30. The conjugate according to claim 26 , wherein the sense strand further comprises a nucleotide sequence 3, and the antisense strand further comprises a nucleotide sequence 4; the nucleotide sequences 3 and 4 have an identical length of 1-4 nucleotides; the nucleotide sequence 3 is linked to 5′ end of the nucleotide sequence 1, and the nucleotide sequence 4 is linked to 3′ end of the nucleotide sequence 2; the nucleotide sequence 4 is complementary to a second nucleotide sequence segment; the second nucleotide sequence segment refers to a nucleotide sequence adjacent to the first nucleotide sequence segment in the target mRNA, and having a same length as the nucleotide sequence 4; and the nucleotide sequence 3 is Substantially reverse complementary, or completely reverse complementary to the nucleotide sequence 4.

31. The conjugate according to claim 26 , wherein the siRNA further comprises a nucleotide sequence 5, which has a length of 1-3 nucleotides and is linked to 3′ end of the antisense strand, thereby constituting a 3′ overhang of the antisense strand.

32. The conjugate according to claim 26 , wherein each nucleotide in the sense and antisense strand is independently a fluoro modified nucleotide or a non-fluoro modified nucleotide, the fluoro modified nucleotide refers to a nucleotide formed by substituting the 2′-hydroxy of the ribose group thereof with a fluoro group; the non-fluoro modified nucleotide refers to a nucleotide formed by substituting the 2′-hydroxy of the ribose group thereof with a group other than a fluoro, or a nucleotide analogue, the nucleotide analogue refers to a group capable of replacing a nucleotide in a nucleic acid, while having a different structure from any one of adenine ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide, uracil ribonucleotide or thymine deoxyribonucleotide.

33. The conjugate according to claim 32 , wherein both of the sense and antisense strand comprises fluoro and non-fluoro modified nucleotides, the fluoro modified nucleotides exist in the nucleotide sequence 1 and the nucleotide sequence 2, no more than 5 fluoro modified nucleotides exist in the nucleotide sequence 1, and in the direction from 5′ terminal to 3′ terminal, the nucleotides at positions 7, 8 and 9 in the nucleotide sequence 1 are fluoro modified nucleotides; no more than 7 fluoro modified nucleotides exist in the nucleotide sequence 2, and in the direction from 5′ terminal to 3′ terminal, the nucleotides at positions 2, 6, 14 and 16 in the nucleotide sequence 2 are fluoro modified nucleotides.

34. The conjugate according to claim 32 , wherein each non-fluoro modified nucleotide is a methoxy modified nucleotide, wherein a methoxy modified nucleotide refers to a nucleotide formed by substituting the 2′-hydroxy of the ribose group thereof with a methoxy group.

35. The conjugate according to claim 26 , wherein in the siRNA, at least one phosphate group is a phosphorothioate group, and a phosphorothioate linkage exists in at least one of following positions:

between the first nucleotide and the second nucleotide from 5′ end of the sense strand;

between the second nucleotide and the third nucleotide from 5′ end of the sense strand;

between the first nucleotide and the second nucleotide from 3′ end of the sense strand;

between the second nucleotide and the third nucleotide from 3′ end of the sense strand;

between the first nucleotide and the second nucleotide from 5′ end of the antisense strand;

between the second nucleotide and the third nucleotide from 5′ end of the antisense strand;

between the first nucleotide and the second nucleotide from 3′ end of the antisense strand; and

between the second nucleotide and the third nucleotide from 3′ end of the antisense strand.

36. The conjugate according to claim 26 , wherein a nucleotide at 5′ end of the antisense strand is a 5′-phosphate nucleotide or a 5′-phosphate analogue modified nucleotide.

37. A method for treating in a subject in need thereof a pathological condition or disease caused by expression of a specific gene in hepatocytes, comprising administering to the subject an effective amount of the conjugate according to claim 14 .

38. The method according to claim 37 , wherein the specific gene is selected from a group consisting of a hepatitis B virus gene, an angiopoietin-like protein 3 gene, and an apolipoprotein C3 gene.

39. The method according to claim 37 , wherein the disease is selected from a group consisting of chronic liver disease, hepatitis, hepatic fibrosis, liver proliferative diseases, and dyslipidemia.

40. The method according to claim 39 , wherein the dyslipidemia is hypercholesterolemia, hypertriglyceridemia, or atherosclerosis.

41. A method for inhibiting expression of a specific gene in hepatocytes, comprising contacting the conjugate according to claim 14 with the hepatocytes.

42. The method according to claim 41 , wherein the specific gene is ApoB, ApoC, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV or HCV.